Evidence map›Paper›PMID 39130151›Full record

ReviewGastro hep advances2023

One-year Increment Staging Incidence of Esophageal Adenocarcinoma With Enhanced Ethnicity Surveillance, Epidemiology, and End Results Program 18 Sampling, 2000-2017.

E M Montminy, M Zhou, J H Bommireddipally, J J Karlitz, S Wani

Erratum issuedAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Gastro hep advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

E M MontminyDivision of Gastroenterology, Tulane University School of Medicine, New Orleans, Louisiana.
M ZhouSouthborough, Massachusetts.
J H BommireddipallyDepartment of Internal Medicine, Tulane University School of Medicine, New Orleans, Louisiana.
J J KarlitzDivision of Gastroenterology and Hepatology, University of Colorado Anschutz Medical Center, Aurora, Colorado.
S WaniDivision of Gastroenterology and Hepatology, University of Colorado Anschutz Medical Center, Aurora, Colorado.

Funding

A Multicenter Randomized Controlled Trial of Surveillance versus. Endoscopic Therapy for Barretts Esophagus with Low-grade Dysplasia: The SURVENT TrialU01DK129191 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI VALERIE L DURKALSKI, NICHOLAS J SHAHEEN · 2022 to 2026
$9.7M
A Multicenter Randomized Controlled Trial of Surveillance versus. Endoscopic Therapy for Barretts Esophagus with Low-grade Dysplasia: The SURVENT TrialU34DK124174 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI DURKALSKI, VALERIE L, SHAHEEN, NICHOLAS J · 2020 to 2020
$384k
NIDDK NIH HHS U01 DK129191NIDDK NIH HHS U34 DK124174
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39130151
PMCPMC11307698

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.